Holen Sie sich die Stockscreener-App
8.64
4.22%
0.35
Handel nachbörslich:
8.57
-0.07
-0.81%
Schlusskurs vom Vortag:
$8.29
Offen:
$8.28
24-Stunden-Volumen:
9.39M
Relative Volume:
2.91
Marktkapitalisierung:
$1.29B
Einnahmen:
$204.73M
Nettoeinkommen (Verlust:
$-184.29M
KGV:
-11.96
EPS:
-0.7226
Netto-Cashflow:
$-51.87M
1W Leistung:
+51.58%
1M Leistung:
+21.69%
6M Leistung:
+178.71%
1J Leistung:
+261.51%
1-Tages-Spanne:
$8.20
$8.87
1-Wochen-Bereich:
$5.53
$8.87
52-Wochen-Spanne:
$2.28
$8.87
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
8.64 | 1.24B | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update - Sahm
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com Nigeria
Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk - Bitget
Maravai Lifesciences Earnings Call Highlights Margin Rebound - TipRanks
MRVI Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 54.65%Post-Announcement Reaction - vinanet.vn
Maravai LifeSciences (MRVI) Slides 1.38% to $5.70 as Key Support Level Comes into FocusALMA Signal - vinanet.vn
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - MarketBeat
Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Stock Price, News & Analysis - Kalkine
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Singapore
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences (MRVI) Plunges 9.92% as Shares Test Critical $5.35 Support ZoneHedge Fund Favorites - vinanet.vn
Maravai LifeSciences Q2 Earnings Call Highlights - TradingView
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Maravai LifeSciences Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-08-06 - Seeking Alpha
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai LifeSciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript - GuruFocus
MRVI: Q2 revenue up 9% to $51.4M; EBITDA guidance raised on margin expansion confidence - TradingView
MRVI: Revenue and margins rose sharply in H1 2026, with net loss narrowing and debt refinanced - TradingView
Maravai LifeSciences Reports Second Quarter 2026 Financial Results - Yahoo Finance
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? - Investing.com
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Slips 2.5% to $6.25 as Key Support NearsInitial Balance - dars.gov.et
Maravai LifeSciences Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Lazard Asset Management LLC Sells 170,919 Shares of Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Downgraded by Wall Street Zen to Hold - MarketBeat
Maravai LifeSciences (MRVI) Expected to Announce Earnings on Thursday - MarketBeat
Maravai LifeSciences Holdings Inc - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Cash Flow - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.760|Chg%:-0.290 - TradingKey
TradingKey - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.690|Chg%:-0.070 - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):